Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity

INTRODUCTION: Locally advanced basal cell carcinoma (laBCC) has always represented an uncommon, difficult-to-treat form of skin cancer, but approval of the Hedgehog inhibitor (HHI) vismodegib has provided an effective, well-tolerated therapy. While this drug has been shown to be a safe and effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Scalvenzi, Massimiliano, Cappello, Milena, Costa, Claudia, Fabbrocini, Gabriella, Luciano, Mariaantonietta, Villani, Alessia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211780/
https://www.ncbi.nlm.nih.gov/pubmed/32240528
http://dx.doi.org/10.1007/s13555-020-00371-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211780/
https://www.ncbi.nlm.nih.gov/pubmed/32240528
http://dx.doi.org/10.1007/s13555-020-00371-1

Ejemplares similares